NYSE:GKOS - New York Stock Exchange, Inc. - US3773221029 - Common Stock - Currency: USD
97.6
0 (0%)
The current stock price of GKOS is 97.6 USD. In the past month the price increased by 6.53%. In the past year, price decreased by -13.32%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.37 | 235.96B | ||
ISRG | INTUITIVE SURGICAL INC | 67.04 | 183.58B | ||
BSX | BOSTON SCIENTIFIC CORP | 36.94 | 147.56B | ||
SYK | STRYKER CORP | 30.11 | 144.19B | ||
MDT | MEDTRONIC PLC | 15.87 | 111.93B | ||
BDX | BECTON DICKINSON AND CO | 12.22 | 49.36B | ||
EW | EDWARDS LIFESCIENCES CORP | 28.9 | 44.08B | ||
IDXX | IDEXX LABORATORIES INC | 45.85 | 42.36B | ||
RMD | RESMED INC | 27.46 | 36.56B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.71 | 33.08B | ||
DXCM | DEXCOM INC | 49.69 | 32.15B | ||
STE | STERIS PLC | 25.84 | 23.71B |
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in Aliso Viejo, California and currently employs 995 full-time employees. The company went IPO on 2015-06-25. The firm is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
GLAUKOS CORP
1 Glaukos Way
Aliso Viejo CALIFORNIA 92672 US
CEO: Thomas W. Burns
Employees: 995
Phone: 19493679600
The current stock price of GKOS is 97.6 USD.
The exchange symbol of GLAUKOS CORP is GKOS and it is listed on the New York Stock Exchange, Inc. exchange.
GKOS stock is listed on the New York Stock Exchange, Inc. exchange.
21 analysts have analysed GKOS and the average price target is 126.14 USD. This implies a price increase of 29.24% is expected in the next year compared to the current price of 97.6. Check the GLAUKOS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GLAUKOS CORP (GKOS) has a market capitalization of 5.58B USD. This makes GKOS a Mid Cap stock.
GLAUKOS CORP (GKOS) currently has 995 employees.
GLAUKOS CORP (GKOS) has a support level at 93.22 and a resistance level at 97.61. Check the full technical report for a detailed analysis of GKOS support and resistance levels.
The Revenue of GLAUKOS CORP (GKOS) is expected to grow by 26.94% in the next year. Check the estimates tab for more information on the GKOS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GKOS does not pay a dividend.
GLAUKOS CORP (GKOS) will report earnings on 2025-07-29, after the market close.
GLAUKOS CORP (GKOS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.42).
The outstanding short interest for GLAUKOS CORP (GKOS) is 6.07% of its float. Check the ownership tab for more information on the GKOS short interest.
ChartMill assigns a technical rating of 2 / 10 to GKOS. When comparing the yearly performance of all stocks, GKOS is a bad performer in the overall market: 76.52% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to GKOS. GKOS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months GKOS reported a non-GAAP Earnings per Share(EPS) of -1.42. The EPS increased by 40.34% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -12.8% | ||
ROE | -16.19% | ||
Debt/Equity | 0.09 |
ChartMill assigns a Buy % Consensus number of 83% to GKOS. The Buy consensus is the average rating of analysts ratings from 21 analysts.
For the next year, analysts expect an EPS growth of 54.21% and a revenue growth 26.94% for GKOS